Infinimmune Partners With Merck To Discover And Develop Therapeutic Antibodies Using Human-First AI Platform; Merck Will Have The Exclusive Right To Develop And Commercialize Antibody Candidates Arising From The Collaboration; Infinimmune Will Receive An Undisclosed Upfront Payment And Is Eligible To Receive Milestone Payments Associated With The Progress Of Multiple Antibody Candidates All Totaling Up To ~$838M

• Collaboration aims to discover and develop antibodies against multiple therapeutic targets designated by Merck
• Infinimmune's platform combines large-scale human immune repertoire single cell screening with AI-guided antibody engineering to rapidly identify and optimize therapeutic candidates

ALAMEDA, Calif.--(BUSINESS WIRE)--Infinimmune, a biotechnology company pioneering antibody discovery and design, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Infinimmune's human-first antibody discovery platform to identify and develop antibody candidates against multiple undisclosed targets designated by Merck.

Under the agreement, Infinimmune will use its proprietary Anthrobody® discovery platform and GLIMPSE™ antibody language model to discover and optimize therapeutic antibodies derived directly from human immune repertoires. The Infinimmune platform enables the screening of millions of single memory B cells across hundreds of potential targets, identifying natively paired antibody candidates and enabling the rapid identification of candidates with strong affinity, specificity, and favorable drug-like properties.

Merck will have the exclusive right to develop and commercialize antibody candidates arising from the collaboration. Under the terms of the agreement, Infinimmune will receive an undisclosed upfront payment and is eligible to receive milestone payments associated with the progress of multiple antibody candidates all totaling up to approximately $838 million.